Amphastar Pharmaceuticals (AMPH) Operating Leases (2019 - 2026)

Amphastar Pharmaceuticals' Operating Leases history runs 8 years deep, the most recent figure standing at $75.1 million for Q1 2026.

• In Q1 2026, Operating Leases rose 84.59% year-over-year to $75.1 million; the TTM figure through Mar 2026 stood at $75.1 million (up 84.59% YoY), while the FY2025 annual figure was $37.7 million, down 10.02% from the prior year.
• Operating Leases was $75.1 million for Q1 2026 at Amphastar Pharmaceuticals, up from $37.7 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $75.1 million in Q1 2026 to a low of $23.7 million in Q4 2022.
• Historically, Operating Leases has averaged $33.4 million across 5 years, with a median of $29.5 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Operating Leases dropped 10.02% in 2025, then soared 84.59% in 2026.
• A 5-year view of Operating Leases shows it stood at $23.7 million in 2022, then advanced by 25.44% to $29.7 million in 2023, then jumped by 40.91% to $41.9 million in 2024, then fell by 10.02% to $37.7 million in 2025, then soared by 99.39% to $75.1 million in 2026.
• The last three Operating Leases figures came in at $75.1 million (Q1 2026), $37.7 million (Q4 2025), and $39.4 million (Q3 2025), per Business Quant data.